| Names | |
|---|---|
| IUPAC name (1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.16,9.02,7]tetracosa-2,5,7,14-tetraen-4-one | |
| Systematic IUPAC name (1R,9S,10S,12S,14E,16S,19R,20R,21S,22R)-3,9,21-Trihydroxy-5,10,12,14,16,20,22-heptamethyl-23,24-dioxatetracyclo[17.3.1.16,9.02,7]tetracosa-2,5,7,14-tetraen-4-one | |
| Other names (-)-TAN 2162 | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider | |
| MeSH | C485395 |
PubChem CID | |
CompTox Dashboard (EPA) | |
| |
| |
| Properties | |
| C29H42O6 | |
| Molar mass | 486.64 g/mol |
| Appearance | Yellow powder |
| Solubility in DMSO, methanol | Soluble |
| Hazards | |
| Occupational safety and health (OHS/OSH): | |
Main hazards | Toxic |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
Kendomycin is an anticancer macrolide first isolated from Streptomyces violaceoruber . [2] It has potent activity as an endothelin receptor antagonist and anti-osteoporosis agent. [3] It also has strong cytotoxicity against various tumor cell lines. [2]
Because of its potent biological activities, kendomycin has attracted interest as a target of total synthesis. The first total synthesis of kendomycin was accomplished by Lee and Yuan in 2004. [4] The total number of syntheses stands at 6. [5] [6] [7] [8] [9]